45 research outputs found
Significant CD4, CD8, and CD19 Lymphopenia in Peripheral Blood of Sarcoidosis Patients Correlates with Severe Disease Manifestations
BACKGROUND: Sarcoidosis is a poorly understood chronic inflammatory condition. Infiltration of affected organs by lymphocytes is characteristic of sarcoidosis, however previous reports suggest that circulating lymphocyte counts are low in some patients with the disease. The goal of this study was to evaluate lymphocyte subsets in peripheral blood in a cohort of sarcoidosis patients to determine the prevalence, severity, and clinical features associated with lymphopenia in major lymphocyte subsets. METHODOLOGY/PRINCIPAL FINDINGS: Lymphocyte subsets in 28 sarcoid patients were analyzed using flow cytometry to determine the percentage of CD4, CD8, and CD19 positive cells. Greater than 50% of patients had abnormally low CD4, CD8, or CD19 counts (p<4x10(-10)). Lymphopenia was profound in some cases, and five of the patients had absolute CD4 counts below 200. CD4, CD8, and CD19 lymphocyte subset counts were significantly correlated (Spearman's rho 0.57, p = 0.0017), and 10 patients had low counts in all three subsets. Patients with severe organ system involvement including neurologic, cardiac, ocular, and advanced pulmonary disease had lower lymphocyte subset counts as a group than those patients with less severe manifestations (CD4 p = 0.0043, CD8 p = 0.026, CD19 p = 0.033). No significant relationships were observed between various medical therapies and lymphocyte counts, and lymphopenia was present in patients who were not receiving any medical therapy. CONCLUSIONS/SIGNIFICANCE: Significant lymphopenia involving CD4, CD8, and CD19 positive cells was common in sarcoidosis patients and correlated with disease severity. Our findings suggest that lymphopenia relates more to disease pathology than medical treatment
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; pâ=â0.40). There was no significant effect of DMF on any secondary outcome
Acquired hypogammaglobulinemia and pathogenâspecific antibody depletion after solid organ transplantation in human immunodeficiency virus infection: A brief report
Hypogammaglobulinemia (HGG) frequently occurs in recipients after types of (SOT). The incidence and significance of HGG in HIV+Â recipients of SOT are just being explored. We reported that 12% of the recipients in the SOT in multiâcenter HIVâTR (HIVâTR) Study developed moderate or severe HGG at 1Â year. In LT recipients, this was associated with serious infections and death. We have now further characterized the decreased antibodies in HIV+Â SOT recipients who developed HGG. We measured the levels of pathogenâspecific antibodies and polyâspecific selfâreactive antibodies (PSA) in relation to total IgG levels from serial serum samples for 20 HIV+Â SOT recipients who developed moderate to severe HGG following SOT. Serum antibody levels to measles, tetanus toxoid, and HIVâ1 were determined by EIA. Levels of PSAs were determined by incubating control lymphocytes with patient serum, staining with antiâhuman IgG FabâFITC, and analysis by flow cytometry. Levels of PSA were higher compared to healthy, HIVâuninfected controls at preâtransplant baseline and increased by weeks 12 and 26, but the changes were not significant. Likewise, antiâHIV antibody levels remained unchanged over time. In contrast, antibody levels against measles and tetanus were significantly reduced from baseline by week 12, and did not return to baseline, even after 2Â years. For HIV patients who develop moderate to severe HGG after transplant, the reduction in IgG levels is associated with a significant decrease in pathogenâspecific antibody titers, while PSA levels and antiâHIV antibodies are unchanged. This may contribute to infectious complications and other clinical endpoints.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/152685/1/tid13188_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/152685/2/tid13188.pd
Acquired hypogammaglobulinemia and pathogenâspecific antibody depletion after solid organ transplantation in human immunodeficiency virus infection: A brief report
Hypogammaglobulinemia (HGG) frequently occurs in recipients after types of (SOT). The incidence and significance of HGG in HIV+Â recipients of SOT are just being explored. We reported that 12% of the recipients in the SOT in multiâcenter HIVâTR (HIVâTR) Study developed moderate or severe HGG at 1Â year. In LT recipients, this was associated with serious infections and death. We have now further characterized the decreased antibodies in HIV+Â SOT recipients who developed HGG. We measured the levels of pathogenâspecific antibodies and polyâspecific selfâreactive antibodies (PSA) in relation to total IgG levels from serial serum samples for 20 HIV+Â SOT recipients who developed moderate to severe HGG following SOT. Serum antibody levels to measles, tetanus toxoid, and HIVâ1 were determined by EIA. Levels of PSAs were determined by incubating control lymphocytes with patient serum, staining with antiâhuman IgG FabâFITC, and analysis by flow cytometry. Levels of PSA were higher compared to healthy, HIVâuninfected controls at preâtransplant baseline and increased by weeks 12 and 26, but the changes were not significant. Likewise, antiâHIV antibody levels remained unchanged over time. In contrast, antibody levels against measles and tetanus were significantly reduced from baseline by week 12, and did not return to baseline, even after 2Â years. For HIV patients who develop moderate to severe HGG after transplant, the reduction in IgG levels is associated with a significant decrease in pathogenâspecific antibody titers, while PSA levels and antiâHIV antibodies are unchanged. This may contribute to infectious complications and other clinical endpoints.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/152685/1/tid13188_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/152685/2/tid13188.pd